The Bionicure hydrogel depot entraps a cargo drug until a small molecule triggers the dissolution of the hydrogel depot thereby releasing the cargo drug.
No molecular modification of the cargo drug is required for formulation with the Bionicure hydrogel depot.
The Bionicure hydrogel is cross-linked through a specific biological interaction that can be inhibited by competitive substitution through a molecular trigger.
All components of the Bionicure formulation and the trigger are generally recognized as safe and already in clinical use for many years. The trigger is orally available and the hydrogel components as well as the trigger are readily cleared after dissolution.